阿巴西普、利妥昔单抗与托珠单抗治疗类风湿关节炎总体感染风险的观察性队列研究
该研究基于丹麦DANBIO注册库,纳入2010至2017年起始非TNF抑制剂治疗的RA患者,比较阿巴西普、利妥昔单抗与托珠单抗的总体感染风险,感染定义为抗生素处方或感染相关住院。0至12个月利妥昔单抗年龄性别调整感染发生率数值上最高,但校正后相对风险置信区间较宽,差异可能部分由适应证混杂解释。
要点
- 非TNF抑制剂治疗的RA患者总体感染常见,0至12个月利妥昔单抗发生率数值上最高。
- 校正后三种药物间相对风险接近1,置信区间较宽,不能排除无差异。
- 换药者与既往吸烟者感染风险分别高于生物制剂初治者与从不吸烟者。
核心结论
- 在非TNF抑制剂治疗的RA患者中总体感染常见,利妥昔单抗有风险最高的倾向,但所有分析置信区间较宽,适应证混杂可能至少部分解释差异。
研究设计与样本
- 观察性队列研究,纳入DANBIO注册库中2010至2017年起始非TNF抑制剂治疗的RA患者,共3696个治疗疗程(阿巴西普1115、利妥昔单抗1017、托珠单抗1564)。
- 感染定义为抗生素处方或感染相关住院,通过链接国家注册库获取处方、合并症与感染数据,计算年龄性别调整发生率及校正后率比(Poisson回归)。
主要发现
- 0至12个月共发生1747次感染。
- 年龄性别调整每100人年感染发生率为阿巴西普76(95%CI:69,84)、利妥昔单抗87(95%CI:79,96)、托珠单抗77(95%CI:71,84)。
- 校正后相对风险:阿巴西普对比利妥昔单抗0.94(95%CI:0.81,1.08),托珠单抗对比利妥昔单抗0.94(95%CI:0.81,1.03),阿巴西普对比托珠单抗1.00(95%CI:0.88,1.14)。
- 24个月后相对风险仍接近1。
- 换药者较生物制剂初治者、既往吸烟者较从不吸烟者感染风险更高。
临床怎么用
- 对起始非TNF抑制剂治疗的RA患者应关注总体感染风险,尤其换药者与既往吸烟者。
- 三种药物间感染风险差异证据不确定,选择时不宜仅依据感染风险差异。
局限性
- 为观察性研究,存在适应证混杂可能。
- 各分析置信区间较宽,相对风险估计不精确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Most infections in patients with RA are treated in primary care with antibiotics. A small fraction require hospitalization. Only a few studies exist regarding the overall risk of infection (i.e. prescription of antibiotics or hospitalization due to infection) in patients initiating non-TNF-inhibitor therapy. In Danish RA patients initiating abatacept, rituximab and tocilizumab treatment in routine care, the aims were to compare adjusted incidence rates (IR) of infections and to estimate relative risk of infections across the drugs during 0-12 and 0-24 months. METHODS: This was an observational cohort study including all RA patients in the DANBIO registry starting a non-TNF-inhibitor from 2010 to 2017. Infections were defined as a prescription of antibiotics or hospitalization due to infection. Prescriptions, comorbidities and infections were captured through linkage to national registries. IRs of infections (age, gender adjusted) and rate ratios (as estimates of RR (relative risk)), adjusted for additional covariates) (Poisson regression) were calculated. RESULTS: We identified 3696 treatment episodes (abatacept 1115, rituximab 1017, tocilizumab 1564). At baseline, rituximab users were older and had more previous cancer. During 0-12 months, 1747 infections occurred. Age and gender-adjusted IRs per 100 person-years were as follows: abatacept: 76 (95% CI: 69, 84); rituximab: 87 (95% CI: 79, 96); tocilizumab: 77 (95% CI: 71, 84). Adjusted RRs were 0.94 (95% CI: 0.81, 1.08) for abatacept and 0.94 (95% CI: 0.81, 1.03) for tocilizumab compared with rituximab and 1.00 (95% CI: 0.88, 1.14) for abatacept compared with tocilizumab. RRs around 1 were observed after 24 months. Switchers and ever smokers had higher risk compared with biologic-naïve and never smokers, respectively. CONCLUSION: Overall infections were common in non-TNF-inhibitor-treated RA patients, with a tendency towards rituximab having the highest risk, but CIs were wide in all analyses. Confounding by indication may at least partly explain any differences.
引用
- Grøn KL, Glintborg B, Nørgaard M, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology (Oxford). 2020. PMID: 31764977. doi:10.1093/rheumatology/kez530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。